Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY-0102 Monotherapy in Advanced Solid Tumors
NCT04914351Phase 1Completed
- Sponsor
- Shanghai HyaMab Biotechnology
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HY-0102 in solid tumor, sponsored by Shanghai HyaMab Biotechnology. Primary endpoints: Occurrence of Drug Limited Toxicities at 28 days, Incidence of Treatment-emergent adverse event and serious adverse events and 4 more. Started May 2022; status: completed.
02
Drugs
HY-0102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04914351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914351.